Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.

McMahon, Moira Aa; Siliciano, Janet Db; Kohli, Rahul Mb; Siliciano, Robert Fb,c

doi: 10.1097/QAD.0b013e32833424e5
Research Letters

Trials of acyclovir for herpes simplex virus 2 infection in herpes simplex virus 2/HIV-1 coinfected patients not on antiretroviral therapy demonstrated a decrease in herpes simplex virus 2 and HIV-1 replication. Recent studies indicated that acyclovir has direct anti-HIV-1 activity and can select for the HIV-1 V75I reverse transcriptase variant in vitro. We show that the V75I variant has decreased sensitivity to some nucleoside analogs but an increased sensitivity to zidovudine, results that may guide selection of highly active antiretroviral therapy regimens in patients harboring this variant.

aDepartment of Pharmacology and Molecular Sciences, USA

bDepartment of Medicine, Johns Hopkins University School of Medicine, USA

cHoward Hughes Medical Institute, Baltimore, Maryland, USA.

Received 16 September, 2009

Revised 7 October, 2009

Accepted 13 October, 2009

© 2010 Lippincott Williams & Wilkins, Inc.